Welcome to our dedicated page for Healthcare Triangle SEC filings (Ticker: HCTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Healthcare Triangle, Inc. filings document material-event reporting, shareholder voting matters, capital-structure changes, acquisition records, and governance disclosures for a healthcare information technology company. Recent 8-K filings cover the company’s Nasdaq-listed common stock, emerging growth company status, board-approved share repurchase program, and the completed reverse stock split reflected in amendments to its certificate of incorporation.
The filing record also includes proxy materials for a special stockholder meeting and material-agreement disclosures tied to subsidiary transactions. An amended 8-K provides acquired-business financial statements and pro forma financial information for Teyamé 360 S.L. and Datono Mediación S.L., connecting transaction disclosures with HCTI’s broader AI, digital health, and customer-engagement platform activity.
Healthcare Triangle, Inc. reported much larger scale in the quarter ended March 31, 2026, following its acquisition of Teyame and Datono. Net revenue rose to $9.86 million from $3.70 million, mainly from the new Customer Engagement Services segment. Gross margin improved to $2.39 million, but the company recorded a larger net loss of $6.20 million, versus $1.70 million a year earlier, driven by higher operating expenses, amortization and a $2.44 million loss from changes in fair value of 2025 convertible notes.
Total assets increased to $80.16 million, reflecting recognition of $55.22 million in other intangible assets and $2.95 million of goodwill tied to acquisitions. Cash and cash equivalents were $4.32 million, with negative operating cash flow of $6.86 million and $6.02 million used in investing mainly for the Teyame acquisition, partially offset by $9.48 million provided by financing activities.
At March 31, 2026, total current and long‑term liabilities were $27.47 million, including short‑term borrowings and debt with credit institutions of $9.09 million, and contingent consideration of $5.00 million. Stockholders’ equity expanded to $52.70 million, aided by equity issuances, preferred stock arrangements and conversion of 2025 debentures into common shares. After a 1‑for‑60 reverse stock split, there were 2,027,783 common shares outstanding as of May 13, 2026. Management acknowledges prior operating losses and negative cash flows but concludes, based on net assets and subsequent equity proceeds, that it has sufficient resources to meet obligations for at least twelve months.
Healthcare Triangle, Inc. filed an amended 2025 annual report to correct a clerical error in its auditor’s signature, without changing previously issued financial disclosures. For 2025, the company generated net revenue of $13.9 million and recorded a net loss of $9.5 million, reflecting higher operating expenses and interest costs.
Cash and cash equivalents rose to $7.6 million, supported by $17.0 million of equity issuance and new 2025 senior unsecured convertible notes with a face value of $15.0 million, measured at fair value of $10.5 million at year-end. Management acknowledged past losses and negative operating cash flow but concluded available cash, net assets and post-year-end equity raises are sufficient to fund operations for at least twelve months.
Healthcare Triangle, Inc. files its annual report describing a cloud-focused healthcare IT business built around proprietary platforms like CloudEz, DataEz, Readabl.AI, Ziloy.AI and Ezovion. The company targets healthcare providers and Life Sciences firms with managed cloud, data and interoperability services.
Healthcare Triangle highlights rapid growth in healthcare cloud, data science, AI and IT services markets, while warning of intense competition, heavy regulation, cybersecurity exposure and reliance on major cloud vendors. The report notes two recent reverse stock splits and significant revenue concentration among a small number of large customers.
Healthcare Triangle, Inc. entered into a Platform Development Agreement with SecureKloud Technologies and its subsidiary Blockedge to build an integrated health advisory and care platform, including document management artificial intelligence tools, for use in the company’s commercial offerings.
The project term began on March 31, 2026 and is expected to finish within 12 to 15 months, but no later than September 30, 2027. All intellectual property rights in the deliverables, including enhancements and derivative works, will be owned exclusively by Healthcare Triangle, with no ongoing royalties or commissions to SecureKloud or Blockedge.
The agreement acknowledges prior advances of about $3.48 million to SecureKloud and $0.345 million to Blockedge, which will be offset against future invoices. The total project budget is capped at $3.0 million plus a $0.2 million contingency, and Healthcare Triangle will not make additional payments until these advances are fully settled.
Healthcare Triangle, Inc. files an amended report to supply full financial details for its newly acquired Spanish subsidiaries Teyamé 360 S.L. and Datono Mediación S.L. The amendment includes audited 2024–2025 statements and unaudited pro forma combined figures, showing both businesses were profitable with multi‑million‑dollar annual revenue before acquisition.
Healthcare Triangle, Inc. amends its at-the-market program to increase the amount available for sale to $39,000,000 of common stock under the Sales Agreement with Spartan Capital Securities, LLC. This supplement notes $6,522,300.16 of shares were previously sold under the ATM Agreement and that sales may be made on Nasdaq or otherwise in at-the-market transactions.
The Sales Agent will sell on a commercially reasonable efforts basis and is not required to sell any specific number or dollar amount. The last reported sale price on Nasdaq on March 30, 2026 was $2.71 per share.
Healthcare Triangle, Inc. has authorized a new share repurchase program allowing the company to buy back up to $2,000,000 of its outstanding common stock. The Board approved the 2026 Share Repurchase Plan on March 9, 2026, and it became effective immediately.
The company may repurchase shares over time through open market purchases, privately negotiated transactions, or other methods in line with securities laws, including Rule 10b-18 and potential Rule 10b5-1 trading plans. Management will decide the timing and volume of any repurchases based on market conditions, the stock price, liquidity needs, legal requirements, and other factors.
The program does not require the company to repurchase any specific number of shares and can be suspended, modified, or discontinued at any time. Any shares bought back may be held as treasury stock or retired. Management describes the plan as part of a prudent capital allocation approach and a sign of confidence in the company’s long-term strategy.
Healthcare Triangle, Inc. reports via a Schedule 13G/A that Orca Capital beneficially owns 2,033 shares of common stock, equal to 0.2% of the class.
Ownership percentages are calculated based on 1,155,370 shares outstanding immediately after the issuer's registered offering as stated in the prospectus supplement filed pursuant to Rule 424(b)(5) on February 27, 2026.
Healthcare Triangle, Inc. Schedule 13G shows Orca Capital beneficially owns 86,058 shares of Common Stock, representing 7.4% of the class as reported immediately after the issuer's registered offering and tied to an aggregate outstanding count of 1,155,370 shares described in the prospectus supplement. The filing lists sole voting and dispositive power over 86,058 shares and is signed by Thomas Konig on 03/02/2026.
Healthcare Triangle, Inc. entered into a registered direct offering for 681,553 shares of common stock (or pre-funded warrants in lieu thereof) at $5.81 per share, for aggregate gross proceeds of approximately $3.95 million before fees and expenses.
The deal includes 421,553 common shares and 260,000 pre-funded warrants, which are immediately exercisable at $0.00001 per share and subject to beneficial ownership caps of 4.99% or 9.99%. The company plans to use the net proceeds for working capital and general corporate purposes.
D. Boral Capital LLC acted as sole placement agent and received a cash fee equal to 7% of the aggregate gross proceeds plus expense reimbursement. The securities were issued off an effective Form S-3 shelf registration statement and a prospectus supplement dated February 26, 2026.